Poseida Therapeutics Inc (PSTX)
$9.51 $0.02 (0.16%) 4:37 PM 12/14/24
NASDAQ | $USD | BiotechnologyStock Data
-
Market Cap
$912.29M -
Day's Range
$9.48 - $9.55 -
Volume
3,475,045 -
52 Week Low / High
$1.87 - $9.44 -
PE Ratio
- -
PEG Ratio
- -
Dividend Frequency
-
- Capital Growth
- Dividend Return to Date
- Dividend Payout year Est.
- Expenses
- Total Return
- Total Return %
- 0
- Strong Buy
- 0
- Buy
- 5
- Hold
- 0
- Sell
- 0
- Strong Sell
- $12.25
- Target Price
Company News
-
MaxCyte Appoints Cynthia Collins to its Board of Directors — Oct 15th, 2024
MaxCyte, Inc ROCKVILLE, Md., Oct. 15, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeut...
-
Poseida Therapeutics Highlights Recent Progress, Strategic Priorities and Anticipated 2024 Key Milestones — Jan 4th, 2024
Reported positive early clinical data for allogeneic myeloma cell therapy P-BCMA-ALLO1 at ASH 2023 supporting potential of TSCM-rich allogeneic CAR-T to offer a differentiated and compelling efficacy, safety, and reliability profile that could compete with autologous CAR-T Plan to report ...
-
MaxCyte Appoints Cynthia Collins to its Board of Directors — Oct 15th, 2024
MaxCyte, Inc ROCKVILLE, Md., Oct. 15, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeut...
-
MaxCyte Appoints Cynthia Collins to its Board of Directors — Oct 15th, 2024
MaxCyte, Inc ROCKVILLE, Md., Oct. 15, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeut...
-
MaxCyte Appoints Cynthia Collins to its Board of Directors — Oct 15th, 2024
MaxCyte, Inc ROCKVILLE, Md., Oct. 15, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeut...
-
MaxCyte Appoints Cynthia Collins to its Board of Directors — Oct 15th, 2024
MaxCyte, Inc ROCKVILLE, Md., Oct. 15, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeut...
-
MaxCyte Appoints Cynthia Collins to its Board of Directors — Oct 15th, 2024
MaxCyte, Inc ROCKVILLE, Md., Oct. 15, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeut...
-
MaxCyte Appoints Cynthia Collins to its Board of Directors — Oct 15th, 2024
MaxCyte, Inc ROCKVILLE, Md., Oct. 15, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeut...
-
MaxCyte Appoints Cynthia Collins to its Board of Directors — Oct 15th, 2024
MaxCyte, Inc ROCKVILLE, Md., Oct. 15, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeut...
Similar Stocks
Portfolio
Comprised of 1 portfolios